Tesla (TSLA) To Report Q2 Earnings: What's In The Cards?

Tesla, Inc. (NASDAQ:TSLA) is scheduled to report second-quarter 2019 results on Jul 24. In the last reported quarter, its earnings and revenues missed the Zacks Consensus Estimate.

In the past six months, shares of Tesla have underperformed the industry it belongs to. During that period, the stock has lost 10.3% against the industry’s growth of 5%.

Along with strong delivery of Model 3 sedan, the company’s energy generation and storage revenues for the soon-to-be-released quarter are likely to remain robust mainly due to the storage business. Tesla expects the gross margin of the energy business to grow in the quarter.

With a better supply of cells and new manufacturing equipment, the company aims to increase energy storage deployments in 2019.

Tesla currently carries a Zacks Rank #3 (Hold). It expects long-term growth rate to be 35%. Over the past month, the Zacks Consensus Estimate for current-year loss has narrowed down from $1.23 to $1.11.

Tesla has an Earnings ESP of -25.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Stocks to Consider

Here are a few auto stocks worth considering, comprising the right combination of elements to come up with an earnings beat this time around:

Cummins Inc (NYSE:CMI) currently has an Earnings ESP of +3.48% and a Zacks Rank of 3. It is slated to release second-quarter 2019 results on Jul 30. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Penske Automotive Group, Inc (NYSE:PAG) presently has an Earnings ESP of +0.42% and a Zacks Rank of 3. It is slated to release second-quarter 2019 results on Jul 30.

Dana Incorporated (NYSE:DAN) currently has an Earnings ESP of +0.45% and a Zacks Rank of 3. It is slated to release second-quarter 2019 results on Jul 31.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>